<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02403271</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-1135-CA</org_study_id>
    <nct_id>NCT02403271</nct_id>
  </id_info>
  <brief_title>A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors</brief_title>
  <official_title>A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Durvalumab (MEDI4736), in Subjects With Relapsed or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacyclics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2, multi-center study to assess the safety and efficacy of ibrutinib in
      combination with Durvalumab (MEDI4736) in subjects with relapsed or refractory solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Phase 1b: Number of participants with adverse events as a measure of safety and tolerability of ibrutinib and MEDI4736 and to find the recommended Phase II dose.</measure>
    <time_frame>Up to 28 days after last subject enrolled.</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Efficacy of ibrutinib in combination with MEDI4736 in subjects with relapsed or refractory solid tumors by assessing the ORR per RECIST 1.1.</measure>
    <time_frame>When the last subject enrolled completes at least 2 response assessments after at least 5 cycles of treatment estimated to be approximately 140 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Pharmacokinetics of ibrutinib.</measure>
    <time_frame>Cycle 3 Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax: The peak plasma concentration of ibrutinib after administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Pharmacokinetics of ibrutinib.</measure>
    <time_frame>Cycle 3 Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC0-24: The area under the plasma concentration-time curve of ibrutinib after administration form time zero to 24 hrs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Pharmacokinetics of MEDI4736</measure>
    <time_frame>Cycle 6 Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax: The peak plasma concentration of MEDI4736 after administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Pharmacokinetics of MEDI4736</measure>
    <time_frame>Cycle 6 Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ctrough: The trough plasma concentration of MEDI4736.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Pharmacodynamics</measure>
    <time_frame>At selected timepoints through cycle 4 estimated to be up to 112 days after initial dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Occupancy assays for ITK and other targets in the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Number of participants with adverse events as a measure of safety and tolerability of ibrutinib and MEDI4736</measure>
    <time_frame>Up to 28 days after last subject enrolled.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Pharmacokinetics of ibrutinib</measure>
    <time_frame>Cycle 3 Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax: The peak plasma concentration of ibrutinib after administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Pharmacokinetics of ibrutinib</measure>
    <time_frame>Cycle 3 Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC0-24: The area under the plasma concentration-time curve of ibrutinib after administration from zero to 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Pharmacokinetics of MEDI4736</measure>
    <time_frame>Cycle 6 Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax: The peak plasma concentration of MEDI4736 after administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Pharmacokinetics of MEDI4736</measure>
    <time_frame>Cycle 6 Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ctrough: The trough plasma concentration of MEDI4736.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Pharmacodynamics</measure>
    <time_frame>At selected timepoints through cycle 4 estimated to be up to 112 days after initial dose.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Occupancy assays for ITK and other targets in the blood.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1b/2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1b: Subjects will receive ibrutinib daily in combination with Durvalumab (MEDI4736) IV at various dose levels to determine the Recommended Phase II dose level. (ENROLLMENT COMPLETED IN PHASE 1b)
Phase 2: Subjects will receive ibrutinib daily in combination with Durvalumab (MEDI4736) IV at the Recommended Phase II dose level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>BTK Inhibitor</description>
    <arm_group_label>Phase 1b/2</arm_group_label>
    <other_name>PCI-32765</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab (MEDI4736)</intervention_name>
    <description>Anti PDL-1</description>
    <arm_group_label>Phase 1b/2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathologically confirmed:

               -  Non-small cell lung cancer (NSCLC, adenocarcinoma or squamous-cell carcinoma) or

               -  Breast cancer (HER2 positive or triple negative)

          2. Relapsed or refractory disease (Stage III or IV): NSCLC cancer must have failed at
             least 1 prior treatment. Breast cancer must have failed at least 2 prior treatments.

          3. Measurable lesion by RECIST 1.1

          4. Adequate hematologic function:

               -  ANC &gt;1500 cells/mm3

               -  Platelet count &gt;100,000 cells/mm3

               -  HGB &gt;9.0 g/dL

          5. Adequate hepatic and renal function:

               -  AST and ALT ≤2.5 x ULN for subjects without liver metastases and ≤3.5 x ULN for
                  subjects with liver metastases

               -  Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of
                  non-hepatic origin)

               -  Creatinine ≤2.0 x ULN or Creatinine Clearance ≥40 mL/min

          6. PT/INR &lt;1.5 x ULN and PTT/ aPTT &lt;1.5 x ULN

        Exclusion Criteria:

          1. Mixed small cell and NSCLC histology

          2. A history of CNS involvement except as follows: Subjects with previously treated CNS
             metastases that are adequately treated with whole brain radiotherapy, that are
             neurologically stable, and do not require corticosteroids for symptomatic management
             for at least 14 days prior to first dose of study drug. There must be no clear
             evidence of radiographically active disease for at least 90 days prior to enrollment.

          3. Anti-tumor therapy within 21 days of study Day 1

          4. Prior treatment with ibrutinib or other BTK inhibitor anti-CD137 or CTLA-4 antibody.
             The following are exceptions to this criterion: Subjects previously treated with an
             anti-PD1, anti-PD-L1, or anti-PD-L2 antibody.

          5. History of allogeneic organ transplant

          6. Treatment with a strong cytochrome P450 (CYP) 3A inhibitor
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isaiah Dimery</last_name>
    <role>Study Director</role>
    <affiliation>Pharmacyclics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Molly Mallough</last_name>
    <phone>408-215-3743</phone>
    <email>mmallough@pcyc.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Mallough</last_name>
      <phone>408-215-3743</phone>
      <email>mmallough@pcyc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Mallough</last_name>
      <phone>408-215-3743</phone>
      <email>mmallough@pcyc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Mallough</last_name>
      <phone>408-215-3743</phone>
      <email>mmallough@pcyc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Mallough</last_name>
      <phone>408-215-3743</phone>
      <email>mmallough@pcyc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Mallough</last_name>
      <phone>408-215-3743</phone>
      <email>mmallough@pcyc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Mallough</last_name>
      <phone>408-215-3743</phone>
      <email>mmallough@pcyc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Mallough</last_name>
      <phone>408-215-3743</phone>
      <email>mmallough@pcyc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Mallough</last_name>
      <phone>408-215-3743</phone>
      <email>mmallough@pcyc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Mallough</last_name>
      <phone>408-215-3743</phone>
      <email>mmallough@pcyc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Mallough</last_name>
      <phone>408-215-3743</phone>
      <email>mmallough@pcyc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Mallough</last_name>
      <phone>408-215-3743</phone>
      <email>mmallough@pcyc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Mallough</last_name>
      <phone>408-215-3743</phone>
      <email>mmallough@pcyc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Mallough</last_name>
      <phone>408-215-3743</phone>
      <email>mmallough@pcyc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Mallough</last_name>
      <phone>408-215-3743</phone>
      <email>mmallough@pcyc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Mallough</last_name>
      <phone>408-215-3743</phone>
      <email>mmallough@pcyc.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 3, 2016</lastchanged_date>
  <firstreceived_date>February 27, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacyclics</keyword>
  <keyword>PCYC</keyword>
  <keyword>Ibrutinib</keyword>
  <keyword>Durvalumab (MEDI4736)</keyword>
  <keyword>Relapsed Refractory Solid Tumor</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>triple negative</keyword>
  <keyword>HER2 positive</keyword>
  <keyword>Her2+ Breast Cancer</keyword>
  <keyword>Squamous</keyword>
  <keyword>Squamous NSCLC</keyword>
  <keyword>Squamous Non-Small Cell Lung Cancer</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>IMBRUVICA®</keyword>
  <keyword>Tumor Immunotherapy</keyword>
  <keyword>Anti-PD-L1</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
